Cherrystone portfolio company bought for $140 million

BOSTON HEART DIAGNOSTICS, a bio-analytical testing and genomic service founded in 2007, and which Cherrystone Angel Group supported in 2009 with an investment, has been sold for $140 million to Eurofins Scientific.
BOSTON HEART DIAGNOSTICS, a bio-analytical testing and genomic service founded in 2007, and which Cherrystone Angel Group supported in 2009 with an investment, has been sold for $140 million to Eurofins Scientific.
(Updated, 5:14 p.m.) BOSTON – A Cherrystone Angel Group portfolio business has entered into an acquisition agreement worth $140 million with a European buyer specializing in bio-analytical testing and genomic services. Boston Heart Diagnostics, a heart health management company, will be purchased by Eurofins Scientific, pending post-closing adjustments. The sellers’ earn-out payments are expected to…

Want More?

Subscribe or register with Providence Business News to keep reading.

REGISTER
for 2 more stories

Subscribe now for $1 for 4 weeks
Already a Subscriber? Login now

Purchase NowWant to share this story? Click Here to purchase a link that allows anyone to read it on any device whether or not they are a subscriber.

- Advertisement -

No posts to display